For: | Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023; 29(34): 5020-5037 [PMID: 37753366 DOI: 10.3748/wjg.v29.i34.5020] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm |
Number | Citing Articles |
1 |
Rongzhong Wang, Shiyan Wang, Hua Jiang, Yingmei Lan, Shaobin Yu. Prospects for the clinical application of exosomal circular RNA in squamous cell carcinoma. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1430684
|
2 |
Young Seob Shin, Jeong Yun Jang, Ye Jin Yoo, Jesang Yu, Kye Jin Song, Yoon Young Jo, Sung-Bae Kim, Sook Ryun Park, Ho June Song, Yong-Hee Kim, Hyeong Ryul Kim, Jong Hoon Kim. Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae060
|
3 |
Chao Zhao, Hui Han, Yushuang Tian, Guangjin Qu, Yingying Xu, Yihan Wang, Lili Shi. Identification of genome-wide copy number variation-driven subtypes for the treatment and prognostic prediction of esophageal carcinoma. Heliyon 2024; 10(19): e38011 doi: 10.1016/j.heliyon.2024.e38011
|
4 |
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
|
5 |
Jindan Kai, Kai Kang, Zhixiao Jiang, Fei Xiong, Sheng Wang. Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation. Heliyon 2024; 10(13): e33567 doi: 10.1016/j.heliyon.2024.e33567
|
6 |
Junhan Wu, Xin Xia, Longlong Gong, Shujie Huang, Hongbo Zheng, Guibin Qiao, Yong Tang. Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration. Human Vaccines & Immunotherapeutics 2024; 20(1) doi: 10.1080/21645515.2024.2370085
|
7 |
Bo Yang, Wei Gou, Naiying Lan, Qing Shao, Weifeng Hu, Cheng Xue, Nanmei Liu. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1347896
|
8 |
Zhengzhou Qiu, Zhao Li, Xingfei Liu, Ruilin Zhang, Yongxuan Li, Chenggen Gao, Xiaoling Mao, Yin Bao, Mingyue Zhang, Changying Guo. From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1478922
|
9 |
Mohamed Wishahi. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World Journal of Hepatology 2024; 16(4): 490-493 doi: 10.4254/wjh.v16.i4.490
|